PRTODAY / NewswireToday Free press release distribution service network

Written by / Agency / Source: Frost & Sullivan

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Frost & Sullivan Enabling Technology Award Conferred on Alexza Pharmaceuticals for Staccato® - Pioneering technology supports non-invasive, rapid-acting and patient-friendly therapy options for acute agitation in bipolar disorder patients
Frost & Sullivan Enabling Technology Award Conferred on Alexza Pharmaceuticals for Staccato®

 

NewswireToday - /newswire/ - London, United Kingdom, 2012/10/18 - Pioneering technology supports non-invasive, rapid-acting and patient-friendly therapy options for acute agitation in bipolar disorder patients.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Based on its recent analysis of the bipolar disorder therapeutics market, Frost & Sullivan recognises Alexza Pharmaceuticals with the 2012 Global Enabling Technology Award for its core proprietary technology - Staccato®.

Staccato® is a novel method of inhaled drug delivery that is exclusively customised for conditions requiring rapid speed of therapeutic effect, reliable dosing and ease-of-use. Currently, Alexza Pharmaceuticals has developed a single-dose disposable platform and a multi-dose platform with reusable controller. The Staccato® system eliminates the need for excipients and additives, such as detergents, solvents and stabilisers, thereby reducing the possible associated side-effects for patients.

ADASUVE™ (Staccato® loxapine) is the flagship product of Alexza Pharmaceuticals, based on Staccato® platform, which is being developed for the acute treatment of agitation associated with bipolar disorder or schizophrenia. ADASUVE™ meets all the three key attributes in the treatment guidelines outlined by the American Association for Emergency Psychiatry - speed of onset, predictability of medication delivery and patient preference.

"With a single normal breath, the Staccato® technology delivers an accurate, rapidly absorbed dose of loxapine through the deep lung," noted Frost & Sullivan Research Analyst Aiswariya Chidambaram. "Loxapine, noted for its excellent receptor-binding attributes and positive side-effect profile, is likely to be a preferred antipsychotic of physicians treating agitation."

At present, nearly 5.7 million and 3.1 million adults in the United States and Europe, respectively, suffer from bipolar disorder. The limitations of current therapies and drugs have highlighted the enormous commercial potential of ADASUVE™.

"ADASUVE™ offers a non-invasive, rapid-acting and patient-friendly therapy option, which ensures safe, effective and early intervention well before the agitation episodes escalate out of control," remarked Chidambaram. "It also offer betters results in emergency conditions, when agitation has reached a crisis level."

Alexza Pharmaceuticals has successfully completed two separate phase III trials for schizophrenia (344 patients) and bipolar disorder (314 patients), wherein ADASUVE™ showed statistically significant primary and secondary endpoint results as compared to placebo.

Alexza Pharmaceuticals anticipates U.S. FDA regulatory approval for ADASUVE™ by the end of 2012 and is projecting a launch of the product by mid-year 2013 in the United States and Europe. This first-in-class, anti-agitation product is expected to hold huge market potential and business opportunities in terms of commercialisation.

"In anticipation of regulatory approval, Alexza Pharmaceuticals has already established strong technology and materials supply relationships and has built a clinical good manufacturing practice (cGMP) facility in California," stated Chidambaram. "The company plans to commercialise this pioneering technology globally and has already been pro-active in forging strategic partnerships with leading pharmaceutical companies."

Frost & Sullivan presents this award to the company for developing a technology that enables the creation of new products and applications and/or enhances current products. The potential for market acceptance and breadth of access to the technology also underpin the receipt of this award.

Frost & Sullivan Best Practices awards recognise companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Industry analysts compare market participants and measure performance through in-depth interviews, analysis, and extensive secondary research to identify best practices in the industry.

About Alexza Pharmaceuticals
Alexza is a pharmaceutical company focused on the research, development and commercialization of novel, proprietary products for the acute treatment of central nervous system conditions. Alexza was founded in 2000 by noted biotechnology and drug delivery entrepreneur, Dr. Alejandro Zaffaroni, with the vision of creating new therapies to treat acute and intermittent medical conditions through a new and novel technology. Alexza's invented technology, the Staccato® system, vaporizes unformulated drug to form a condensation aerosol that, when inhaled, allows for rapid systemic drug delivery through deep lung inhalation. With the Staccato system, a drug is quickly absorbed through the lungs into the bloodstream, providing speed of therapeutic onset that is comparable to intravenous administration, but with greater ease, patient comfort and convenience. Click here to see an animation of how the Staccato system works.

About Frost & Sullivan
Frost & Sullivan (frost.com), the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.

Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.

The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.

For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?

Contact Us: Start the discussion | Join Us: Join our community | Subscribe: Newsletter on "the next big thing" | Register: Gain access to visionary innovation.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Written by / Agency / Source: Frost & Sullivan

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick Newswire Today Visibility Checker

 

Distribution / Indexing: [+] / [Company listed above is a registered member of our network. Content made possible by PRZOOM / PRTODAY indexing services]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Frost & Sullivan Enabling Technology Award Conferred on Alexza Pharmaceuticals for Staccato®

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name Newswire Today and LINK as the source.
 
  Is this your article?
Activate ALL web links and social stream by Upgrading to Press Release PREMIUM Plan Now!

Frost & Sullivan |
Publisher Contact: Kristina Menzefricke 
+44(0)20 7915 7862 kristina.menzefricke[.]frost.com
 
Newswire Today - PRZOOM / PRTODAY disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Frost & Sullivan securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Frost & Sullivan / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Newswires:

Greenphire Sponsors Second Annual Clinical Trial Agreements, Investigator Payments and Fair Market Value Meeting
Genentech’s Gazyva Helped People with Previously Untreated Follicular Lymphoma Live Significantly Longer
BD Announces Adoption of Windows 10 ‘Internet of Things’ for the Pyxis™ ES System
Greenphire Named to Deloitte 2016 Technology Fast 500™
Genentech Showcases New Clinical Data Across a Variety of Blood Diseases at American Society of Hematology 2016 Annual Meeting
BD Collaborates with JDRF to Focus on Extended Wear Innovations for Insulin Infusion Delivery
BD Launches First Syringe Designed for Use with Humulin® R U-500 Insulin
MDxHealth Announces Unique CPT Code Awarded for ConfirmMDx from the American Medical Association
BD MAX™ Vaginal Panel Receives FDA Market Authorization to Detect Most Common Causes of Vaginal Infections
Greenphire Receives EU-US Privacy Shield Certification
The 2016 Georges Mathé Prize Recognizes Research on the Immunological Determinants of the Response to Breast Cancer Treatment
MDxHealth Announces Agreement with HIFU CLINIC Prostate Cancer Center for Distribution of SelectMDx in Poland
First Patient in Malaysia Receives TheraSphere™ Radioembolisation Therapy
FDA Approves Genentech’s Lucentis® (Ranibizumab Injection) Prefilled Syringe
BTG and Mirada Medical Announce CE Mark Certification for Simplicit90Y Dosimetry Software in Europe

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  Triggr & Bloom

Visit  BizJobs.com





 
  ©2016 Newswire Today — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR free press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)